PBLS compared with SGP: revenue, margins and what each company keeps, and the suppliers and customers both name

PBLSParabilis Medicines, Inc.

Mkt capRevenueRevenue

SGPSpyGlass Pharma, Inc.

Mkt capRevenueRevenue

Compare

PBLSParabilis Medicines, Inc.

SGPSpyGlass Pharma, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

PBLS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−4.65%—

SGP1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+2.26%—

= impliedPBLS realized, solidSGP realized, hatchedOne scale, both sides: full bar = 5%× = |realized| ÷ impliedSource: market data

PBLSParabilis Medicines, Inc.

27.29▼−6.70%· post 30.34· delayed

Mkt cap$845.6MRevenue$148,000Q2 FY26

SGPSpyGlass Pharma, Inc.

34.04▼−1.19%· post 34.04· delayed

After hoursNov 4 '26delayed

Mkt cap$1.2BRevenue—

Compare

After hoursNov 4 '26delayed

PBLSParabilis Medicines, Inc.

SGPSpyGlass Pharma, Inc.

27.29▼−6.70%post 30.34delayed

Price

34.04▼−1.19%post 34.04delayed

$845.6M

Mkt cap

$1.2B

Q2 FY26$148,000

Revenue

—

PBLS27.29▼−6.70%vsSGP34.04▼−1.19%After hoursNov 4 '26delayed